Moolec Science (MLECW) Deferred Taxes (2023 - 2024)
Moolec Science (MLECW) posted Deferred Taxes of $280889.0 for Q4 2024, up 1103.57% sequentially from -$27989.0 in Q3 2024, and up 219.03% YoY from $88045.9 in Q1 2024.
Moolec Science (MLECW) Deferred Taxes (2023 - 2024) Analysis & Trends
Moolec Science has reported Deferred Taxes for 2 years, with the latest figure at $280889.0 in Q4 2024.
- Quarterly Deferred Taxes rose 219.03% year-over-year to $280889.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$342804.0 (changed N/A YoY) and the FY2024 annual result came in at -$1.0 million, down 346.4% from the prior year.
- Deferred Taxes grew to $280889.0 in Q4 2024 per MLECW's latest filing, from -$27989.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at $280889.0 in Q4 2024 and troughed at -$722654.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.66 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 280,889.00 |
| Sep 30, 2024 | -27,989.00 |
| Jun 30, 2024 | -722,654.00 |
| Mar 31, 2024 | 126,950.00 |
| Dec 31, 2023 | -235,990.00 |
| Sep 30, 2023 | -215,291.00 |